Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.

Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.

Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.

The company reveals the first overall survival data in adjuvant ER-positive breast cancer.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

The ESMO regular abstract lift reveals first human datasets for several projects.

Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.

The group toplines a phase 2 win with Alphamedix.